The EU GMO Framework Is Slowing Down Gene Therapy. Here's What Regulatory Affairs Teams Need to Do About It.
You've secured your CTA. Your trial is designed. Your sites are ready.
Then the GMO clock starts — and suddenly you're looking at up to 12 months of additional review before a single patient can be treated.
If you work in regulatory affairs for gene therapy medicinal products (GTMPs), this is not a hypothetical. It's a recurring reality that continues to delay access to potentially curative therapies for patients with serious unmet medical needs.
Here's a clear-eyed breakdown of where the framework stands today — and what you can do to navigate it more effectively.
Drop your email to access the full dashboard and stay in control of your GTMP timelines.
ICH M4Q (R2): The biggest rewrite of the CTD Quality Module in two decades .
ICH M4Q(R2) is the biggest rewrite of the CTD Quality module in over 20 years — and adoption is targeted for June 2027.
Module 2.3 is being re-engineered from a summary into the central regulatory narrative, a new DMCS model (Description, Manufacture, Control, Storage) is being applied consistently across every material type, and lifecycle management is being built into the CTD for the first time.
If you author, review, or maintain CTD dossiers, this is worth getting ahead of now rather than in 2027.
I've broken down what's actually changing, what regulators are signalling for the transition, and what it means for CMC and regulatory teams.
Drop your email to access the full dashboard and stay informed on ICH M4Q (R2)
